Bernstein Adjusts PT on Edwards Lifesciences to $96 From $95, Maintains Market Perform Rating

Bernstein has increased its price target for Edwards Lifesciences (EW) to $96 from $95, while maintaining a Market Perform rating. This adjustment follows several other analyst revisions for Edwards Lifesciences on the same day, indicating varied expert opinions on the company’s stock performance despite its recent Q1 earnings beating estimates. The company specializes in cardiovascular medical systems and devices, and its stock has experienced minor fluctuations recently.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin